Roche Glycart Ag

Hoffmann-La Roche Inc.

F. Hoffmann-La Roche Ag

Valeria G Nicolini

Christian Klein

Pablo Umana

Ekkehard Moessner

Ralf Hosse

Anne Freimoser-Grundschober

Thomas U Hofer

Marina Bacac

Pablo Umaña

Inja Waldhauer

Peter Bruenker

Oliver Ast

Sylvia Herter

Laura Codarri Deak

Stefan Seeber

Wolfgang Richter

Alexander Knaupp

Halina Trochanowska

Christian Gerdes

Laura Lauener

Douglas Hanahan

Stephan Wullschleger

Anne Freimoser-grundschober

The invention provides antibodies against Fibroblast Activation Protein (FAP) and methods of using the same.

Anti-FAP antibodies and methods of use

The present invention generally relates to immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. In addition, the invention relates to polynucleotide molecules encoding the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.

Immunoconjugates

The present invention relates to the combination therapy of specific PD-1-targeted IL-2 variant immunocytokines with specific antibodies which bind human PD-L1.

Combination therapy of PD-1-targeted IL-2 variant immunocytokines and antibodies against human PD-L1

The present invention generally relates to antibodies that bind to CD3, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Bispecific antibody molecules binding to CD3 and TYRP-1

The present invention generally relates to antibodies that bind to CD3, including multi specific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Bispecific antibody molecules binding to CD3 and EGFRvIII

The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the &#x3b1;-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.

Mutant interleukin-2 polypeptides

The present invention provides combinations of (a) an immunoconjugate comprising a first antibody engineered to have reduced effector function and an effector moiety, and (b) a second antibody engineered to have increased effector function, for use in treating a disease in an individual in need thereof. Further provided are pharmaceutical compositions comprising the combinations, and methods of using them.

Combination IL-2 immunoconjugate therapy

The invention provides antibodies against the A2 domain of tenascin-C and methods of using the same.

Anti-tenascin-C A2 antibodies and methods of use

Growing community of inventors

Erlenbach, Switzerland

Valeria G Nicolini